CTLA4 and renal cell carcinoma: With the advent of novel immune checkpoint inhibitor (ICI) targeting programmed death-1 (PD-1), programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4), the treatment paradigm of RCC has changed tremendously[4,7,8].